In one way, if it did have serious adverse effects then maybe they could enter the rodent extermination sector of the economy.
They have other products for epilepsy and dementia - but they claim that CimetreATM is their most "advanced" product - and it has no FDA approval yet. That does not say very much about their product lines.
"..demonstrated anti inflammatory and immuomodulating properties." - this is not unique in the world of inflammatory medications - and miost cold and flu/allergy medications can do this already.
Still, a step closer to FDA approval is something. Key Highlights: • MGC Pharma has completed the full pre-clinical rodents study panel for CimetrATM. • The latest study, which was carried out at the Smart Assays laboratory in Israel, included the development of bioanalytical methods and validations for further pharmacokinetic analysis for CimetrATM. • A study on chronic toxicity in rodents was also completed by Science in Action, in Israel, monitoring the potential development of adverse effects from using CimetrATM. • Histopathology demonstrated the full safety profile for CimetrATM across all study dosage groups. • The study results are an important step ahead of the submission to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) approval. • No anomalies were observed in the biopsies, nor were any clinical or behavioural adverse events recorded. • CimetrATM is MGC Pharma’s proprietary Investigational Medicinal Product which in previous clinical trials has demonstrated anti-inflammatory and immunomodulating properties, and is MGC’s most clinically advanced product.
MXC Price at posting:
1.1¢ Sentiment: None Disclosure: Not Held
